A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity
Increasing evidence has shown that Parkinson’s disease (PD) impairs midbrain dopaminergic, cortical and other neuronal subtypes in large part due to the build-up of lipid- and vesicle-rich α-synuclein (αSyn) cytotoxic inclusions. We previously identified stearoyl-CoA desaturase (SCD) as a potential...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294123/ https://www.ncbi.nlm.nih.gov/pubmed/35445353 http://dx.doi.org/10.1007/s13311-022-01199-7 |
_version_ | 1784749780422885376 |
---|---|
author | Nuber, Silke Chung, Chee Yeun Tardiff, Daniel F. Bechade, Pascal A. McCaffery, Thomas D. Shimanaka, Kazuma Choi, Jeonghoon Chang, Belle Raja, Waseem Neves, Esther Burke, Christopher Jiang, Xin Xu, Ping Khurana, Vikram Dettmer, Ulf Fanning, Saranna Rhodes, Kenneth J. Selkoe, Dennis J. Scannevin, Robert H. |
author_facet | Nuber, Silke Chung, Chee Yeun Tardiff, Daniel F. Bechade, Pascal A. McCaffery, Thomas D. Shimanaka, Kazuma Choi, Jeonghoon Chang, Belle Raja, Waseem Neves, Esther Burke, Christopher Jiang, Xin Xu, Ping Khurana, Vikram Dettmer, Ulf Fanning, Saranna Rhodes, Kenneth J. Selkoe, Dennis J. Scannevin, Robert H. |
author_sort | Nuber, Silke |
collection | PubMed |
description | Increasing evidence has shown that Parkinson’s disease (PD) impairs midbrain dopaminergic, cortical and other neuronal subtypes in large part due to the build-up of lipid- and vesicle-rich α-synuclein (αSyn) cytotoxic inclusions. We previously identified stearoyl-CoA desaturase (SCD) as a potential therapeutic target for synucleinopathies. A brain-penetrant SCD inhibitor, YTX-7739, was developed and has entered Phase 1 clinical trials. Here, we report the efficacy of YTX-7739 in reversing pathological αSyn phenotypes in various in vitro and in vivo PD models. In cell-based assays, YTX-7739 decreased αSyn-mediated neuronal death, reversed the abnormal membrane interaction of amplified E46K (“3K”) αSyn, and prevented pathological phenotypes in A53T and αSyn triplication patient-derived neurospheres, including dysregulated fatty acid profiles and pS129 αSyn accumulation. In 3K PD-like mice, YTX-7739 crossed the blood–brain barrier, decreased unsaturated fatty acids, and prevented progressive motor deficits. Both YTX-7739 treatment and decreasing SCD activity through deletion of one copy of the SCD1 gene (SKO) restored the physiological αSyn tetramer-to-monomer ratio, dopaminergic integrity, and neuronal survival in 3K αSyn mice. YTX-7739 efficiently reduced pS129 + and PK-resistant αSyn in both human wild-type αSyn and 3K mutant mice similar to the level of 3K-SKO. Together, these data provide further validation of SCD as a PD therapeutic target and YTX-7739 as a clinical candidate for treating human α-synucleinopathies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13311-022-01199-7. |
format | Online Article Text |
id | pubmed-9294123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-92941232022-07-20 A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity Nuber, Silke Chung, Chee Yeun Tardiff, Daniel F. Bechade, Pascal A. McCaffery, Thomas D. Shimanaka, Kazuma Choi, Jeonghoon Chang, Belle Raja, Waseem Neves, Esther Burke, Christopher Jiang, Xin Xu, Ping Khurana, Vikram Dettmer, Ulf Fanning, Saranna Rhodes, Kenneth J. Selkoe, Dennis J. Scannevin, Robert H. Neurotherapeutics Original Article Increasing evidence has shown that Parkinson’s disease (PD) impairs midbrain dopaminergic, cortical and other neuronal subtypes in large part due to the build-up of lipid- and vesicle-rich α-synuclein (αSyn) cytotoxic inclusions. We previously identified stearoyl-CoA desaturase (SCD) as a potential therapeutic target for synucleinopathies. A brain-penetrant SCD inhibitor, YTX-7739, was developed and has entered Phase 1 clinical trials. Here, we report the efficacy of YTX-7739 in reversing pathological αSyn phenotypes in various in vitro and in vivo PD models. In cell-based assays, YTX-7739 decreased αSyn-mediated neuronal death, reversed the abnormal membrane interaction of amplified E46K (“3K”) αSyn, and prevented pathological phenotypes in A53T and αSyn triplication patient-derived neurospheres, including dysregulated fatty acid profiles and pS129 αSyn accumulation. In 3K PD-like mice, YTX-7739 crossed the blood–brain barrier, decreased unsaturated fatty acids, and prevented progressive motor deficits. Both YTX-7739 treatment and decreasing SCD activity through deletion of one copy of the SCD1 gene (SKO) restored the physiological αSyn tetramer-to-monomer ratio, dopaminergic integrity, and neuronal survival in 3K αSyn mice. YTX-7739 efficiently reduced pS129 + and PK-resistant αSyn in both human wild-type αSyn and 3K mutant mice similar to the level of 3K-SKO. Together, these data provide further validation of SCD as a PD therapeutic target and YTX-7739 as a clinical candidate for treating human α-synucleinopathies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13311-022-01199-7. Springer International Publishing 2022-04-20 2022-04 /pmc/articles/PMC9294123/ /pubmed/35445353 http://dx.doi.org/10.1007/s13311-022-01199-7 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Nuber, Silke Chung, Chee Yeun Tardiff, Daniel F. Bechade, Pascal A. McCaffery, Thomas D. Shimanaka, Kazuma Choi, Jeonghoon Chang, Belle Raja, Waseem Neves, Esther Burke, Christopher Jiang, Xin Xu, Ping Khurana, Vikram Dettmer, Ulf Fanning, Saranna Rhodes, Kenneth J. Selkoe, Dennis J. Scannevin, Robert H. A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity |
title | A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity |
title_full | A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity |
title_fullStr | A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity |
title_full_unstemmed | A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity |
title_short | A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity |
title_sort | brain-penetrant stearoyl-coa desaturase inhibitor reverses α-synuclein toxicity |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294123/ https://www.ncbi.nlm.nih.gov/pubmed/35445353 http://dx.doi.org/10.1007/s13311-022-01199-7 |
work_keys_str_mv | AT nubersilke abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT chungcheeyeun abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT tardiffdanielf abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT bechadepascala abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT mccafferythomasd abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT shimanakakazuma abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT choijeonghoon abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT changbelle abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT rajawaseem abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT nevesesther abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT burkechristopher abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT jiangxin abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT xuping abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT khuranavikram abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT dettmerulf abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT fanningsaranna abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT rhodeskennethj abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT selkoedennisj abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT scannevinroberth abrainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT nubersilke brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT chungcheeyeun brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT tardiffdanielf brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT bechadepascala brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT mccafferythomasd brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT shimanakakazuma brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT choijeonghoon brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT changbelle brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT rajawaseem brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT nevesesther brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT burkechristopher brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT jiangxin brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT xuping brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT khuranavikram brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT dettmerulf brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT fanningsaranna brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT rhodeskennethj brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT selkoedennisj brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity AT scannevinroberth brainpenetrantstearoylcoadesaturaseinhibitorreversesasynucleintoxicity |